What is UBS's price target for AMED?

UBS's latest stated price target for Amedisys Inc (AMED) is $95, from its action on Aug 2, 2022.

What is UBS's rating on AMED?

UBS rates AMED Sell, a bearish rating, as of Aug 2, 2022.

When did UBS last change its view on AMED?

On Aug 2, 2022, UBS downgrades to Sell from Neutral, price target $145 to $95.

UBS AMED price target and rating history

UBS rates Amedisys Inc (AMED) Sell with a $95 price target, as of its latest action on Aug 2, 2022. It has published 3 rating actions on AMED since September 2021, including 1 upgrade and 1 downgrade.

Current rating: Sell
Price target: $95
Median target, all firms: Too few
Actions on AMED: 3

UBS price target on AMED

UBS price target on AMED, each point a stated target, September 2021 to August 2022.

Every UBS rating on AMED

Aug 2, 2022
DowngradeUBS downgrades to Sell from Neutral, price target $145 to $95
Mar 1, 2022
UpgradeUBS upgrades to Neutral from Sell, price target $168
Sep 24, 2021
InitiateUBS starts coverage at Sell, price target $150

Questions about UBS and AMED

What is UBS's price target for AMED?: UBS's latest stated price target for Amedisys Inc (AMED) is $95, from its action on Aug 2, 2022.
What is UBS's rating on AMED?: UBS rates AMED Sell, a bearish rating, as of Aug 2, 2022.
When did UBS last change its view on AMED?: On Aug 2, 2022, UBS downgrades to Sell from Neutral, price target $145 to $95.

More AMED rating histories

All UBS ratings AMED news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.